G1 Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Welcome everyone to the 39th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team.
Our next presenting company is G1 Therapeutics. And speaking on behalf of the company, we have CEO, Jack Bailey. (Operator Instructions)
With that, I will pass it over to Jack.
Thank you, Anupam. I'm especially excited to be presenting today because G1 Therapeutics stands on the cusp of our first FDA product approval and launch for our lead therapy, trilaciclib. I will share with you today why we are confident we will be successful with this initial indication and how it represents the first step in what we believe is a much larger opportunity for trilaciclib across multiple tumor types going forward.
On Slide 2, given I'll be making forward-looking statements, obviously, normal safe
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
